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Purpose:We discuss our experiences with fractionated stereotactic radiotherapy (FSR) in the treatment of cavern-
ous sinus meningiomas.
Methods and Materials: From 1995 to 2006, we monitored 100 patients diagnosed with cavernous sinus meningi-
omas; 84 female and 16 male patients were included. The mean patient age was 56 years. The most common
symptoms were a reduction in visual acuity (57%), diplopia (50%), exophthalmy (30%), and trigeminal neuralgia
(34%). Surgery was initially performed on 26 patients. All patients were treated with FSR. A total of 45 Gy was
administered to the lesion, with 5 fractions of 1.8 Gy completed each week. Patient treatment was performed using
a Varian Clinac linear accelerator used for cranial treatments and a micro-multileaf collimator.
Results: No side effects were reported. Mean follow-up period was 33 months, with 20% of patients undergoing
follow-up evaluation of more than 4 years later. The tumor control rate at 3 years was 94%. Three patients re-
quired microsurgical intervention because FSR proved ineffective. In terms of functional symptoms, an 81% im-
provement was observed in patients suffering from exophthalmy, with 46% of these patients being restored to full
health. A 52% improvement was observed in diplopia, together with a 67% improvement in visual acuity and
a 50% improvement in type V neuropathy.
Conclusions: FSR facilitates tumor control, either as an initial treatment option or in combination with microsur-
gery. In addition to being a safe procedure with few side effects, FSR offers the significant benefit of superior func-
tional outcomes.  2009 Elsevier Inc.
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The treatment of cavernous sinus meningiomas (CSM) has
progressed over the past 20 years. This transformation has re-
sulted in part from the contribution of anatomical imaging
(MR and CT), which has facilitated early diagnostics. How-
ever, the emergence of radiosurgery, and more recently of
fractionated stereotactic radiotherapy (FSR), has played the
most significant role in the development of treatment thera-
pies. These therapies have proved their worth by facilitating
both good tumor control (1–4) and significant functional
preservation (5–7). Surgery offers excellent tumor control;
however, the benefits are limited by a considerable level of
functional impairment.
FSR combines the radiobiological benefits of dose frac-
tionation with the precision afforded by the stereotactic ap-
proach. Stereotactic localizer and repositioning allows us to
use a lower margin (2 mm) and complex ballistic to obtain
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10a greater gradient between meningioma and normal tissues,
especially for optic nerve.
This article discusses the results of our study of FSR treat-
ment, carried out for 100 consecutive cases in which CSM
tumors were clearly indicated by anatomical imaging.
METHODS AND MATERIALS
Patients
From 1990 to 2006, we monitored 100 consecutive cases in which
CSM tumors were clearly indicated by anatomical imaging and ac-
companied by corresponding symptoms. An overview is provided in
Table 1. The mean patient age during treatment was 56 years (range,
30–73); 84% of the patients treated were female, which is typical for
this type of pathology (1, 4, 7–9). Twenty-six percent of the patients
were initially treated with what was assumed to be complete surgery.
Secondary growth followed, diagnosed on the basis of worsening
functional symptoms and confirmed by anatomical imaging.
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khar (10) to perform pretreatment grading of the CSM. The results
were relatively homogenous, with 8% of tumors being classified
as Grade I, 38% as Grade II, 30% as Grade III, 10% as Grade IV,
and 8% as Grade V.
Functional symptoms
The following symptoms were observed: headaches (19.5%),
oculomotor dysfunction (50%), trigeminal neuralgia (34%), exoph-
thalmos (30%), and optic nerve dysfunction, resulting in a reduction
in visual acuity (57%).
These symptoms were especially prevalent in those patients who
had previously been operated on, with 34% experiencing headaches,
50% showing oculomotor dysfunction, 37.5% experiencing trigem-
inal neuralgia, 37.5% experiencing exophthalmos, and 67% show-
ing a reduction in visual acuity. Seven of these patients suffered
complete loss of vision in one eye following surgery.
Radiotherapy
All patients were treated with fractionated stereotactic radiother-
apy using the technique previously described (3). A total of 45 Gy
was administered to the lesion across 25 fractions. Isodose coverage
of 90% was achieved, with five fractions of 1.8 Gy per week. Patient
positioning on the treatment table was performed using a BrainLab
(BrainLab, Munich, Germany) stereotactic ring combined with
a thermoplastic mask (Fig. 1). CT localization was carried out for
all patients, followed by MR imaging. Image fusion and treatment
planning were then performed using the BrainLab planning station
(Fig. 2). Patient treatment was performed using a 8-MV Varian Cli-
nac (Varian Medical Systems, Palo Alto, CA) linear accelerator used
for cranial treatments and a BrainLab micro-multileaf collimator.
Dose was delivered through 4–5 arctherapies, with dynamic colli-
mation technique for the previous year. Planned target volume
was defined as gross target volume plus a 2-mm margin. Maximal
dose to normal optic nerve was 4.44 Gy (range, 0.53–4.44 Gy).
Clinical follow-up for each patient (general, ophthalmological,
and paraclinical examinations with MR anatomical imaging) was
performed every 6 months during the first year and once yearly
thereafter. Follow-up at began at the end of FSR.
Follow-up and statistical analysis
The mean follow-up period was 33 months, with 36% of patients
undergoing follow-up evaluation more than 36 months later, 24%
Table 1. Summary of the main characteristics presented by
the patients in our study















Exophthalmos 30%more than 48 months later, and 8% more than 10 years later. Fol-
low-up evaluations performed at 48 months are significant because
the risk of side effects associated with radiotherapy can be assumed
to have decreased by 85% by that time (11).
RESULTS
Tumor control
Following radiotherapy, 9% of the tumors had decreased
in volume. The volume of 88% of the tumors was un-
changed. Three percent of the tumors were found to have
increased in volume at three follow-up evaluations (14,
46, and 108 months). The three patients in question re-
quired microsurgery following radiotherapy. This treatment
approach was indicated on the basis of tumor growth asso-
ciated with worsening symptoms. In each case, an anatom-
ical pathology examination indicated a typical meningioma
with a high proliferation index. The probability curve for
tumor control showed a rate of 94% at both 3 years and
7 years (Fig. 3). These results are reasonably similar to
those published for other FSR (Brell et al., 93% at 4 years
[1] and radiosurgery studies (Roche et al., 92.8% at 5 years;
[7], Pollock and Stafford, 98% at 1 year and 85% at 3
years [6], Mettelus et al., 94.4% at 5 and 10 years [8]);
see Table 2.
Functional symptoms and complications
No side effects related to FSR were reported during fol-
low-up; in particular, there was no neuropathic toxicity.
The functional effects of FSR are summarized in Fig. 4.
Overall, improvement was seen in 67% of those patients
suffering from a reduction in visual acuity, 81% of those suf-
fering from exophthalmos, 50% of those suffering from facial
neuralgia, 52% of those suffering from oculomotor dysfunc-
tion, and 44% of those suffering from headaches. In cases in
whom symptoms worsened (3 patients), this was invariably
associated with tumor regrowth. Following radiotherapy,
Fig. 1. Reusable BrainLab thermoplastic mask.
1014 I. J. Radiation Oncology d Biology d Physics Volume 74, Number 4, 2009Fig. 2. Dose planning: anatomic (MR) images overlaid with dose planning data.these patients found that their initial symptoms worsened at
different intervals (14, 46, and 108 months), with changes
in the tumor volume as indicated by anatomical imaging
necessitating additional microsurgery.
DISCUSSION
Over the past 20 years, the treatment of CSM has pro-
gressed steadily, both in terms of the technologies available
and in terms of the achievable treatment results. Modern
treatment techniques now include resection and tumor con-
trol; however, the essential focus is primarily that of func-
tional conservation.
Although surgery generally facilitates complete tumor ex-
cision, the functional results of surgery alone are accordingly
less than ideal. This can be seen in our study in which patients
who were treated with what was assumed to be complete sur-
gery experienced significantly greater functional impair-
ment—in particular, of the optic nerve (Fig. 5).
FSR is an attractive alternative because it facilitates both
appropriate tumor control (1, 3, 8, 12, 13) and a significant
reduction in functional symptoms. In our study, the best re-
sults were achieved for impaired visual acuity (67% improve-
ment). This appears to be a crucial aspect in the decision to
perform microsurgery alone.
Patients who were initially treated with microsurgery
showed functional improvement not significantly different
from that of patients treated with FSR. The overall resultsare slightly less impressive, because the functional symptoms
before FSR were especially prevalent, particularly in terms of
visual acuity, with seven patients suffering complete loss of
vision in one eye following surgery (Fig. 5).
During patient follow-up, the majority of functional symp-
toms show long-term improvement without relapse. Even if
symptoms either worsen only slightly or not at all, the
Fig. 3. Kaplan-Meyer curve showing the estimated probability
curve for the tumor control rate (n = 100 patients).















Metellus et al., 2005
(8)
RT conf 38 88.6 94.7%
at 5 yrs
60% 47% 50% NC 2
Metellus et al., 2005
(8) Neurosurgery
Gamma knife 36 63.6 94.4%
at 5 yrs
50% 50% 60% NC 2
Roche et al., 2000
(7)
Gamma knife 80 30.5 92.8% at
5 yrs
NC 27% 53% NC 2
Brell et al.,
2006 (1)
FSR 30 50 93%
at 4 yrs
0% 41% 50% 0% 2
Pollock et al., 2004
(6)
Gamma knife 49 58 85%
at 3 yrs
NC 14% 33% NC 2
Our study FSR 100 33 98%
at 3 yrs
67% 52% 50% 81% 3
Abbreviations: FSR = stereotactic fractionated radiotherapy; OM = oculomotor; PFS = Progression-free survival; RT = radiation therapy; RT
conf: conformal radiotherapy.associated patient discomfort differs enormously depending
on the symptom in question. Even if the majority of patients
gradually become accustomed to the residual effects of diplo-
pia or exophthalmos, or to slight headaches, trigeminal neu-
ralgia remains a primarily functional condition. If FSR shows
little or no effect, neuralgia remains a debilitating condition
that generally requires treatment with strong medication, or
even several percutaneous treatments. These in turn carry
a not inconsiderable risk of anesthesia dolorosa.
Thanks to the fractionated dose delivery, FSR facilitates
a considerable reduction in the risk of neuropathy. Symptoms
of this kind were not reported in either our study or that com-
pleted by Brell et al. (1). It is even possible to irradiate the
nerves directly while ensuring appropriate tumor control
and functional control (5).
There is no set dose prescription for CSM treatments. Our
team gradually reduced the total irradiation dose, moving on
average from 55 to 45 Gy, with 90% isodose coverage. This
reduction in dose in turn decreases the risk of toxicity, whileensuring an appropriate tumor control rate. We based this de-
cision on our own expertise with various kinds of irradiated
intracerebral tumor (2, 3, 5, 14).
The results are encouraging compared with treatments
performed using microsurgery alone. In addition to the risk as-
sociated with surgical intervention, the corresponding func-
tional results are less convincing than those achieved with
standard stereotactic radiotherapy. Our results are also encour-
aging compared with treatments performed using microsurgery
alone. In addition to the risk associated with surgical interven-
tion (15–17), the microsurgical results are less successful than
those achieved with standard stereotactic radiotherapy.
Studies examining microsurgical resection of CSMs show
a mortality rate of 1%–10%, with significant postoperative
morbidity in 6%–16% of cases and worsening of functional
symptoms in 16%–35% of cases (15, 16). De Jesus et al.
(16) reported a tumor control rate following total resection
of 94% at 3 years and 81% at 5 years. These statistics differ
from those for the tumor control rate in the case of partialFig. 4. Summary of the progression of the main functional symptoms in patients treated by stereotactic fractionated radio-
therapy.
1016 I. J. Radiation Oncology d Biology d Physics Volume 74, Number 4, 2009Fig. 5. Summary of the progression of the main functional symptoms in patients initially treated with microsurgery before
stereotactic fractionated radiotherapy.resection (87% at 3 years and 67% at 5 years). It is interesting
to note that a study of asymptomatic CSMs that were not
treated shows a median growth rate of approximately 0.24
cm per year (mean follow-up period 47 months) (18). In
the study carried out by Sindou et al. (15) for 100 consecutive
cases, 29% experienced a reduction in visual acuity, 19% oc-
ulomotor dysfunction, and 24% postoperative trigeminal
neuralgia, with a long-term relapse rate of 13.3%.
Given these findings, we do not believe that partial micro-
surgery alone can be considered an appropriate therapy. Al-
though the patients in question experience fewer functional
complications, the tumor control rate is poor. This problem
is evident in the case of large CSM that extend into extra-cav-
ernous regions. Here a combined approach appears to be of
most benefit. Partial tumor resection, preferably in extra-cav-
ernous regions, effectively facilitates a significant reduction
in functional risks while enabling subsequent irradiation of
less significant volumes (19) with radiosurgery or FSR.
The long-term results regarding tumor control rate and func-
tional symptoms are better than those achieved with standard
microsurgery comprising total excision (20).
Radiosurgery can also be considered an attractive alterna-
tive treatment because it facilitates treatment in a single ses-
sion and also offers a tumor control rate comparable to that of
other treatments (see summary of studies in Table 2). How-
ever, there are certain restrictions associated with this tech-
nique. It is not possible to treat lesions with a diameter
> 3.5 cm (21, 22); in addition, treatment delivery in a single
dose presents a risk of further deterioration in neuropathy
(6, 7, 22–26) that can result in loss of the optic nerve. Al-
though the functional results of the various studies publishedREFEshow significant postoperative improvement, this is never-
theless not as impressive as the potential improvement
offered by FSR. Pollock and Stafford (6), for example, found
a 28% improvement in diplopia and 17.5% improvement in
trigeminal neuralgia. Roche et al. (7) reported a 27% im-
provement in oculomotor dysfunction with a 53% improve-
ment in trigeminal neuralgia.
FSR, like any other radiation treatment technique, requires
relatively long-term follow-up. The aim is to monitor the tu-
mor control rate but also to investigate further the complica-
tions associated with the treatment, even though the risks
associated with radiation treatment decrease considerably
after 4 years.
The main treatment techniques all require medium to long-
term monitoring. Ten- to fifteen-year follow-up is necessary
to have greater confidence in long-term tumor control with
using lower doses.
CONCLUSIONS
FSR is the treatment of choice for CSM. It has shown
proven effectiveness both in tumor control and in the im-
provement of functional symptoms, with few side effects.
Validation of results and long-term safety does appear to be
necessary, however. There remain certain indications for
which initial surgery is considered appropriate, for example,
in the case of very large volume tumors.
To summarize, strategies in the treatment of CSMs require
further study, particularly given the current dominance of
surgery, the combined approach, radiosurgery, and FSR in
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